{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:58:41Z","timestamp":1765886321989,"version":"build-2065373602"},"reference-count":33,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto de Salud Carlos III (ISCIII)","award":["PI19\/00631","PI19\/00631"],"award-info":[{"award-number":["PI19\/00631","PI19\/00631"]}]},{"name":"European Union","award":["PI19\/00631","PI19\/00631"],"award-info":[{"award-number":["PI19\/00631","PI19\/00631"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Acquired haemophilia A (AHA) is a rare severe bleeding disorder resulting from the production of autoantibodies directed against coagulation factor VIII. At presentation, bleeding events can be severe, and an early diagnosis and treatment are of major importance. The current study aims to analyse the treated patients who have been diagnosed with AHA for a better understanding of our population and treatment outcome. We conducted a retrospective study with 26 patients who had been diagnosed with AHA and who were treated in our hospital between January 2006 and January 2021. The patients ranged in age from 30 to 85 years old: 46.10% were men, 46.10% had no known underlying condition, 27% had an underlying malignancy, 7.60% presented with other diseases: psoriatic arthritis and Paget\u2019s disease, and 19.30% presented with AHA during puerperium. All of the patients had bleeding events and were treated with bypass agents for this as well as with immunosuppressive therapy to eradicate the inhibitor. A total of 53.80% of the patients had major bleeding. Sixty-nine percent of the patients achieved complete remission, but 26.90% died during the follow-up, although bleeding was not the cause of death in any of these cases. Our observations underline the importance of clinical suspicion and early referral to centres with experience and laboratory facilities for managing AHA.<\/jats:p>","DOI":"10.3390\/jcm11102721","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T10:19:46Z","timestamp":1652264386000},"page":"2721","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Acquired Haemophilia A: A 15-Year Single-Centre Experience of Demography, Clinical Features and Outcome"],"prefix":"10.3390","volume":"11","author":[{"given":"Raisa","family":"Guerrero Camacho","sequence":"first","affiliation":[{"name":"Servicio de Hematolog\u00eda y Hemoterapia, Hospital Universitario La Paz, Paseo de la Castellana 231, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"\u00c1lvarez Rom\u00e1n","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda y Hemoterapia, Hospital Universitario La Paz, Paseo de la Castellana 231, 28046 Madrid, Spain"},{"name":"Coagulopathies and Haemostasis Disorders Group, IdiPAZ, Paseo de la Castellana 231, 28046 Madrid, Spain"},{"name":"Facultad de Medicina, Universidad Aut\u00f3noma de Madrid, Arzobispo Morcillo, 4, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4601-7150","authenticated-orcid":false,"given":"Nora","family":"Butta Coll","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda y Hemoterapia, Hospital Universitario La Paz, Paseo de la Castellana 231, 28046 Madrid, Spain"},{"name":"Coagulopathies and Haemostasis Disorders Group, IdiPAZ, Paseo de la Castellana 231, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damaris","family":"Zagrean","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda y Hemoterapia, Hospital Universitario La Paz, Paseo de la Castellana 231, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Rivas Pollmar","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda y Hemoterapia, Hospital Universitario La Paz, Paseo de la Castellana 231, 28046 Madrid, Spain"},{"name":"Coagulopathies and Haemostasis Disorders Group, IdiPAZ, Paseo de la Castellana 231, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Mart\u00edn Salces","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda y Hemoterapia, Hospital Universitario La Paz, Paseo de la Castellana 231, 28046 Madrid, Spain"},{"name":"Coagulopathies and Haemostasis Disorders Group, IdiPAZ, Paseo de la Castellana 231, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Gasior Kabat","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda y Hemoterapia, Hospital Universitario La Paz, Paseo de la Castellana 231, 28046 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3937-3499","authenticated-orcid":false,"given":"V\u00edctor","family":"Jim\u00e9nez-Yuste","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda y Hemoterapia, Hospital Universitario La Paz, Paseo de la Castellana 231, 28046 Madrid, Spain"},{"name":"Coagulopathies and Haemostasis Disorders Group, IdiPAZ, Paseo de la Castellana 231, 28046 Madrid, Spain"},{"name":"Facultad de Medicina, Universidad Aut\u00f3noma de Madrid, Arzobispo Morcillo, 4, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2298\/SARH10S1064E","article-title":"Acquired haemophilia syndrome: Pathophysiology and therapy","volume":"138","author":"Elezovic","year":"2010","journal-title":"Srp. Arh. Za Celok. Lek."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0950-3536(96)80067-9","article-title":"9 Acquired inhibitors","volume":"9","author":"Cohen","year":"1996","journal-title":"Bailliere\u2019s Clin. Haematol."},{"key":"ref_3","unstructured":"\u00c1lvarez Rom\u00e1n, M.T.M.V., and Jim\u00e9nez Yuste, V. (2016). Hemofilia Adquirida Diagn\u00f3stico Y Tratamiento, Ambos Marketing Services S.L.. [2nd ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1538-7836.2011.04309.x","article-title":"Management of acquired haemophilia A","volume":"9","author":"Collins","year":"2011","journal-title":"J. Thromb. Haemost. JTH"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2141.2003.04162.x","article-title":"Acquired haemophilia: Review and meta-analysis focused on therapy and prognostic factors","volume":"121","author":"Delgado","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0950-3536(98)80049-8","article-title":"Acquired haemophilia","volume":"11","author":"Hay","year":"1998","journal-title":"Bailliere\u2019s Clin. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0038-1650169","article-title":"A survey of 215 non-hemophilic patients with inhibitors to Factor VIII","volume":"45","author":"Green","year":"1981","journal-title":"Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00062752-199502050-00007","article-title":"Factor VIII inhibitors","volume":"2","author":"Hoyer","year":"1995","journal-title":"Curr. Opin. Hematol."},{"key":"ref_9","first-page":"73","article-title":"Immunochemical characterization of factor VIII inhibitors","volume":"150","author":"Hoyer","year":"1984","journal-title":"Prog. Clin. Biol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.1987.00370060073014","article-title":"Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy","volume":"147","author":"Lottenberg","year":"1987","journal-title":"Arch. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajh.20390","article-title":"Acquired hemophilia A: A concise review","volume":"80","author":"Franchini","year":"2005","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2141.1995.tb03294.x","article-title":"Acquired haemophilia and its management","volume":"89","author":"Morrison","year":"1995","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1468-0734.2001.00049.x","article-title":"Acquired hemophilia","volume":"5","author":"Boggio","year":"2001","journal-title":"Rev. Clin. Exp. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2141.2000.02327.x","article-title":"The Diagnosis And Management Of Factor Viii And Ix Inhibitors: A Guideline From The Uk Haemophilia Centre Doctors\u2019organization (UKHCDO)","volume":"111","author":"Hay","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2141.2003.04731.x","article-title":"A population based, unselected, consecutive cohort of patients with acquired haemophilia A","volume":"124","author":"Collins","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired hemophilia A in the United Kingdom: A 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation","volume":"109","author":"Collins","year":"2007","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: Results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J. Thromb. Haemost. JTH"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Andreas","year":"2020","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1471-0528.2012.03469.x","article-title":"Pregnancy-associated acquired haemophilia A: Results from the European Acquired Haemophilia (EACH2) registry","volume":"119","author":"Tengborn","year":"2012","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: Results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired hemophilia A: Results from the European Acquired Haemophilia Registry (EACH2)","volume":"120","author":"Collins","year":"2012","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.revmed.2019.02.008","article-title":"Acquired autoimmune haemophilia: Where is the place of rituximab in the treatment strategy? Reflection from a monocentric series of 8 patients and literature review","volume":"40","author":"Grossin","year":"2019","journal-title":"La Rev. De Med. Interne"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/hae.12138","article-title":"Outcome of acquired haemophilia in France: The prospective SACHA (Surveillance des Auto antiCorps au cours de l\u2019Hemophilie Acquise) registry","volume":"19","author":"Borg","year":"2013","journal-title":"Haemophilia"},{"key":"ref_24","first-page":"241","article-title":"Coagulation tests","volume":"37","year":"2016","journal-title":"Acta Pedi\u00e1t. M\u00e9xico"},{"key":"ref_25","first-page":"612","article-title":"Proceedings: A more uniform measurement of factor VIII inhibitors","volume":"34","author":"Kasper","year":"1975","journal-title":"Thromb. Diath. Haemorrh."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): Results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/MBC.0000000000000582","article-title":"Assessment of acquired hemophilia patient demographics in the United States: The Hemostasis and Thrombosis Research Society Registry","volume":"27","author":"Kessler","year":"2016","journal-title":"Blood Coagul. Fibrinolysis Int. J. Haemost. Thromb."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/hae.13361","article-title":"Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study","volume":"24","author":"Khair","year":"2018","journal-title":"Haemophilia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/hae.12470","article-title":"Similar bleeding phenotype in young children with haemophilia A or B: A cohort study","volume":"20","author":"Clausen","year":"2014","journal-title":"Haemophilia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.2008.001743","article-title":"International recommendations on the diagnosis and treatment of patients with acquired hemophilia A","volume":"94","author":"Baudo","year":"2009","journal-title":"Haematologica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3324\/haematol.10553","article-title":"Rituximab for the treatment of acquired antibodies to factor VIII","volume":"92","author":"Sperr","year":"2007","journal-title":"Haematologica"},{"key":"ref_32","first-page":"396","article-title":"Role of rituximab in the treatment of postpartum acquired haemophilia A: A systematic review of the literature","volume":"13","author":"Bonfanti","year":"2015","journal-title":"Blood Transfus. Trasfus. Del Sangue"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.critrevonc.2006.11.004","article-title":"Rituximab in the treatment of adult acquired hemophilia A: A systematic review","volume":"63","author":"Franchini","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/10\/2721\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:09:24Z","timestamp":1760137764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/10\/2721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["jcm11102721"],"URL":"https:\/\/doi.org\/10.3390\/jcm11102721","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2022,5,11]]}}}